Is tezepelumab more than just an anti-eosinophil drug?
- 31 December 2021
- journal article
- editorial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 59 (1) , 2101700
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Tezepelumab in Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2017
- Epithelial-Derived Cytokines in AsthmaChest, 2017
- KIT Inhibition by Imatinib in Patients with Severe Refractory AsthmaNew England Journal of Medicine, 2017
- Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic ResponsesNew England Journal of Medicine, 2014
- Indirect Challenge TestsChest, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Monitoring asthma therapy using indirect bronchial provocation tests*The Clinical Respiratory Journal, 2007
- Inflammatory subtypes in asthma: Assessment and identification using induced sputumRespirology, 2006
- Mast-Cell Infiltration of Airway Smooth Muscle in AsthmaNew England Journal of Medicine, 2002
- Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic responseThe Lancet, 2000